Changing the Face of Rosacea Management

A supplement to Skin & Allergy News supported by an educational grant from CollaGenex Pharmaceuticals. This supplement was jointly sponsored by The Elsevier Office of Continuing Medical Education (EOCME), an ACCME accredited provider, and Skin & Allergy News.
The articles in this supplement are based on clinical dialogues held with the faculty.

•Topic Highlights
•Faculty
•Target Audience
•Educational Needs
•Learning Objectives
•CME Recognition

To view the supplement, click the image above. To take the CME test, download and print out the PDF file, and follow the test instructions on page 12.

Topic Highlights

• Management of Actinic Keratosis and Malignant Skin Lesions
• Management of Actinic Keratosis
• Challenges of Lentigo Maligna
• Topical Therapy for Cutaneous Metastatic Melanoma

Faculty

Henry H. Roenigk, Jr., MD, Chair
Professor Emeritus
Northwestern University Medical School
Arizona Advanced Dermatology
Scottsdale
Nothing to disclose.

Diane S. Berson, MD
Assistant Professor of Dermatology
Weill Medical College of Cornell University
New York
Consultant for Allergan, Galderma, CollaGenex, Connetics Pharmaceuticals, Medicis Pharmaceuticals Corporation, and Stiefel.

Hilary E. Baldwin, MD
Associate Professor of Clinical Dermatology
Department of Dermatology
SUNY Downstate Medical Center
Brooklyn
Speaker's Bureau for Allergan Inc., Galderma Laboratories, OrthoNeutrogena Corporation, and Stiefel Laboratories; Consultant for CollaGenex Pharmaceuticals.

Diane M. Thiboutot, MD
Professor of Dermatology
The Pennsylvania State University College of Medicine
Hershey
Consultant and has received funding for clinical research from CollaGenex, Galderma, and Intendis, Inc.

Target Audience

This activity has been developed for dermatologists and other healthcare practitioners who manage patients with the signs and symptoms of rosacea.

Educational Needs

Rosacea, which affects approximately 14 million Americans, is a dermatosis of the central part of the face that is characterized by abnormalities in the cutaneous microcirculation. The resulting clinical signs may include persistent erythema, telangiectases, papules and pustules, and ocular involvement. The underlying etiology is unknown, but the failure to demonstrate the presence of pathogens on the skin, and histopathologic findings such as perivascular and follicular leukocytic infiltrates support an inflammatory rather than an infectious process. The appearance of patients with rosacea may be severely affected, resulting in problems with interpersonal interactions and occupational difficulties. Research efforts regarding etiology and treatment options have yielded a significant body of information in the recent medical literature. Among the treatment options that will be discussed are topical agents (metronidazole, sodium sulfacetamide/sulfur, and azelaic acid, as well as some medications that are used which have not been approved by the US Food and Drug Administration), oral medications (including tetracyclines, macrolides, metronidazole, and isotretinoin), and laser and light therapies. This supplement addresses this information in a succinct presentation that will bring practitioners up to date on the most clinically relevant aspects of this topic.

Learning Objectives

By reading and studying this supplement, participants should be able to:

• describe the epidemiology, natural history, and diagnosis of rosacea.

• discuss the most recent research findings regarding the etiology of rosacea.

• explain the growing public health concerns associated with the use of oral antibiotics, the traditional treatment for rosacea.

• discuss topical and oral treatment options for rosacea and the patient selection factors that should be considered in choosing a regimen.

CME Recognition

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and Skin & Allergy News. The EOCME is accredited by the ACCME to provide continuing medical education for physicians.

The EOCME designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits.

Term of Approval: October 2006 to October 31, 2007.

Copyright © 2006 Elsevier Inc.

---